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Abstract The aim of this study was to evaluate cognitive
functioning in newly-diagnosed glioblastoma multiforme
(GBM) patients during treatment with radiotherapy (RT)
plus concomitant and adjuvant temozolomide (TMZ).
Cognitive assessment took place following surgery, but
prior to the start of RT (baseline), after 6 weeks of RT and
concomitant TMZ (1st follow-up), and after three cycles of
adjuvant TMZ (2nd follow-up). Standardized cognitive
summary measures and delta scores for six cognitive
domains were calculated at the individual level. Cognitive
functioning of progression-free GBM patients was com-
pared to that of matched healthy controls. Analyses were
performed on a group of 13 GBM patients that were pro-
gression-free during follow-up. The results showed that the
majority of patients had deficits in multiple cognitive
domains at baseline. Between baseline and 1st follow-up,
four patients improved in one cognitive domain, four
patients deteriorated in one domain, one patient improved in
one domain and deteriorated in another, and four patients
remained stable in all six domains. Between 1st and 2nd
follow-up, the majority of patients (11) remained stable in
all six cognitive domains, whereas one patient declined in
one domain, and one patient showed a deterioration in two
domains. Overall, between baseline and 2nd follow-up,
three patients improved in one cognitive domain, two
patients deteriorated in two domains, one patient improved
in one domain and deteriorated in another, and seven
patients remained stable in all six cognitive domains. In
conclusion, preceding treatment, the majority of GBM
patients show clear-cut deficits in cognitive functioning. In
the course of the first 6 months of their disease, however,
progression-free GBM patients undergoing radiotherapy
plus concomitant and adjuvant temozolomide treatment do
not deteriorate in cognitive functioning.
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Introduction
Glioblastoma multiforme (GBM) is the most aggressive
primary brain tumor. As GBM patients cannot be cured,
treatment procedures primarily focus on extending life
expectancy and palliation of symptoms. Recently, a large
international randomized trial has shown that the addition
of concomitant and adjuvant temozolomide (TMZ) to
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radiotherapy (RT) results in a modest but significant 2.5-
month survival benefit with minimal additional toxicity.
The 2-year survival rate was 26.5% with RT plus TMZ and
10.4% with RT alone [1].
However, the prognosis of GBM patients still remains
poor, with all patients eventually dying due to tumor pro-
gression. Therefore, the quality of survival of these patients
is of major importance. Cognitive deficits, potentially
compromising health-related quality of life, are commonly
observed in GBM patients in different stages of the disease
[2]. It is known that cognitive deficits exist before therapy
starts [3, 4], and remain or worsen in the course of the
disease [5, 6]. A recent study reported a marked decline in
cognitive functioning during and following RT treatment in
high-grade glioma patients who received RT only as
upfront treatment. The cognitive decline was more pro-
nounced in patients with tumor recurrence compared to
progression-free patients, which could be attributed to the
use of anti-epileptic drugs [7].
As treatment methods keep changing and becoming
more aggressive, monitoring possible treatment side-
effects on cognitive functioning remains necessary. An
important question is how cognitive deficits may develop
during this intensified RT and TMZ treatment, compared to
treatment with RT alone, since literature suggests that more
central nervous system toxicity as expressed by radiologi-
cal abnormalities, blood-brain barrier disruption, and cog-
nitive deficits, may ensue due to intensified treatment [8].
While health-related quality of life in newly-diagnosed
GBM patients has already been reported to remain stable
during a regimen of RT and TMZ treatment [9], this study
aims at determining whether this also holds for cognitive
functioning. Therefore, the purpose of the present study is
to prospectively examine cognitive functioning in newly-
diagnosed, progression-free GBM patients, at different
points in time during combined radio-chemotherapy.
Methods
Patients
Consecutive, newly-diagnosed GBM patients were recrui-
ted from the VU University Medical Center, Amsterdam,
The Netherlands, between March 2005 and June 2007. The
inclusion criteria were: (1) histologically confirmed GBM,
(2) no former treatment with radiation or chemotherapy, (3)
age [18 years, and (4) able to communicate in the Dutch
language. After the study protocol was approved by the
local ethics committee, informed consent procedures were
carried out in the postsurgical period, before the start of
radiotherapy.
The treatment regimen was described in detail by Stupp
et al. [1]. In short, all patients underwent neurosurgery
(biopsy or resection) and subsequent treatment with
6 weeks of RT plus concomitant TMZ and six cycles of
adjuvant TMZ. Patients participated in three assessments of
cognitive functioning and magnetic resonance imaging
(MRI): (1) after surgery, but before RT and concomitant
TMZ, (2) after 6 weeks of conventional RT and concom-
itant TMZ, but before adjuvant TMZ, and (3) after three
cycles of adjuvant TMZ. Patients with tumor progression
during treatment were excluded from statistical analyses, to
avoid the possible effects of tumor recurrence on cognitive
functioning.
Normative data of healthy controls were used as a ref-
erence point for interpreting GBM patients’ neuropsycho-
logical test results. These healthy controls were individually
matched with GBM patients with respect to age, sex and
educational level.
Outcome measures
Cognitive functioning was assessed by a battery of stan-
dardized tests. Because of the heterogeneity of both origin
and severity of cognitive impairments in GBM patients, the
battery consisted of a wide variation of tests assessing
multiple cognitive domains. Trained psychometricians
administered a neuropsychological test battery consisting
of the following tests: Letter digit substitution test [10],
Stroop color-word test [10], Concept shifting test [11],
Categoric word fluency test [10], Visual verbal learning
test [10], and Working memory task [12]. To accomplish
data reduction, cognitive summary measures were calcu-
lated to detect possible deficits in the cognitive domains of
(1) information processing speed, (2) psychomotor func-
tion, (3) attention, (4) verbal memory, (5) working mem-
ory, and (6) executive functioning (Table 1). Construction
of these domains was based on a principal component
analysis performed on the performances of healthy con-
trols. Standardized cognitive summary measures (z-scores)
and delta scores (as a measure of change over time) for all
six cognitive domains were calculated at the individual
level.
Statistical analysis
In line with standards used in neuropsychological practice,
an individual z-score of 1.5 or more below that of healthy
controls (z B -1.5) was defined as a clinically significant
deficit in cognitive functioning. Furthermore, a change of
1.5 z-score or more (z (delta) C 1.5 or z (delta) B -1.5)
was defined as a clinically significant improvement or
deterioration.
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Results
Patient characteristics
Analyses were performed on a total of 13 GBM patients.
Six additional patients were excluded because of clinical
and/or radiological tumor progression. All included
patients were progression-free up to at least three cycles of
adjuvant TMZ treatment. Table 2 lists the sociodemo-
graphic and clinical characteristics of these patients.
Changes in anti-epileptic drug use and dexamethasone use
For some patients, changes in baseline AED and dexa-
methasone use (shown in Table 2) occurred during RT and
TMZ treatment. Patient 5 was using AED at baseline, but
continued having frequent seizures. Therefore, the dose of
valproic acid was increased during RT and concomitant
TMZ treatment and once again during the first cycle of
adjuvant TMZ. For patient 9, the dose of phenobarbital was
increased during RT and concomitant TMZ because of
persistent seizures, the dose of valproic acid remained
unchanged. Patient 10 did not use any AED at baseline, but
experienced a seizure during the second adjuvant cycle of
TMZ and therefore started using valproic acid. The dose of
levetiracetam of patient 11 was escalated during RT and
concomitant TMZ because of an increase in partial seizures.
As to the changes in dexamethasone use, patient 3
started using dexamethasone just before the first adjuvant
cycle of TMZ, because of headaches, and continued taking
a low dose of dexamethasone during all adjuvant cycles.
Patient 9 also began using dexamethasone because of
Table 1 Cognitive domains and tests used
Domain Test
Information processing speed Letter digit substitution test (writing condition and reading condition)
Psychomotor function Concept shifting test (condition 0); Letter digit substitution test (Dscore: writing condition-reading condition)
Attention Stroop color-word test (word condition, color condition, color-word condition, and interferention score)
Verbal memory Visual verbal learning test (first trial, total of five trials, Dscore trial 5-trial 1, active delayed recall,
and delayed recognition)
Working memory Working memory task (condition %, conditions with 1 letter, 2 letters, 3 letters, and 4 letters)
Executive functioning Concept shifting test (condition a (numbers), b (letters), c (number-letter)); Categoric word fluency test
Table 2 Clinical variables
Case Age Sex Tumor location Neurosurgical
intervention
Epilepsy
burdena
Anti-epileptic
drugs
Dexamethasone Karnofsky
performance
scale
B FU B FU B FU1 FU2
1 36 Male Right parietotemporal Resection 5 Valproic acid Unchanged No No 90 90 100
2 67 Male Right temporal resection Resection 5 Valproic acid Unchanged No No 90 100 100
3 63 Female Left parietotemporal Resection 1 None Unchanged No Yes 60 60 60
4 50 Female Left frontotemporal Resection 1 None Unchanged No No 90 90 100
5 51 Male Right parietooccipital Biopsy 5 Valproic acid Dose : No No 100 90 90
6 58 Male Right frontal Biopsy 1 None Unchanged No No 90 90 100
7 32 Male Left parietooccipital Resection 1 None Unchanged Yes Yes 90 90 N/A
8 61 Male Left temporal Biopsy 5 Phenitoin Unchanged No No 90 90 90
9 18 Male Right parietotemporal Resection 6 Valproic acid
Phenobarbital
Dose : No Yes 100 90 90
10 63 Male Right frontoparietal Biopsy 1 None Valproic acid Yes No 70 70 70
11 55 Male Left parietal Resection 6 Levetiracetam Dose : No Yes 70 90 90
12 63 Male Left frontal Biopsy 1 None Unchanged No No 90 90 90
13 72 Male Right frontal Biopsy 5 Valproic acid Unchanged No No 90 90 80
a Epilepsy burden: 1 = epilepsy free, 5 = epilepsy, \6 seizures in previous year and on anti-epileptic drugs (AED) mono- or polytherapy,
6 = epilepsy, [6 seizures in previous year and on AED mono- or polytherapy
B Baseline, after surgery, but before RT and TMZ treatment, FU regular, ongoing medical examinations during RT and TMZ treatment (the
exact moment of changes during follow-up are described in the text), FU1 follow-up 1 (after 6 weeks of conventional RT and concomitant TMZ,
but before adjuvant TMZ), FU2 follow-up 2 (after three cycles of adjuvant TMZ), N/A data not available
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headaches, but started during RT and concomitant TMZ,
and continued his use until the second adjuvant cycle of
TMZ. Patient 11 started dexamethasone use during the first
cycle of adjuvant TMZ because of edema and problems in
word finding, and continued using dexamethasone during
all adjuvant cycles of TMZ. The clinical complaints of
these three patients diminished by using dexamethasone
and none of the patients showed radiological signs of tumor
progression.
Cognitive performance
Cognitive functioning was tested in all 13 patients. One
patient (case 3) could not attend to all tests, due to visual
deficits. z-scores and delta-scores of all patients are shown
in Table 3.
Cognitive performance at baseline
Compared to matched healthy controls, 11 patients had
deficits (previously defined as z B -1.5) in one (n = 2) or
multiple (n = 9) cognitive domains at baseline, while 2
patients performed comparable to the healthy population.
Most deficits were found in information processing speed
(n = 8), executive functioning (n = 8) and attention
(n = 6). Fewer deficits were found in working memory
(n = 4) and psychomotor function (n = 2), and only one
patient had a deficit in verbal memory.
Cognitive performance during RT and concomitant TMZ
During this phase of RT and concomitant TMZ treatment,
4 patients showed an improvement (previously defined as z
D C 1.5) in one of the cognitive domains, 4 patients
showed a deterioration (previously defined as z D B -1.5)
in one of the domains, 1 patient improved in one domain
and deteriorated in another, and 4 patients had a stable
performance on all six domains. None of the 13 patients
showed a cognitive decline in more than one domain. At
the end of this period (1st follow-up assessment), 9 patients
had deficits in one (n = 3) or multiple (n = 6) cognitive
domains.
Cognitive performance during adjuvant TMZ
During this phase of adjuvant TMZ treatment, 1 patient
showed a deterioration in one of the cognitive domains, 1
patient showed a deterioration in two domains, and 11
patients remained completely stable on all six domains.
None of the patients showed a deterioration in more than
two cognitive domains. At the end of this period (2nd
follow-up assessment), 11 patients showed deficits in one
(n = 2) or multiple (n = 9) cognitive domains.
Overall cognitive performance
Overall, during 6 weeks of RT plus concomitant TMZ
treatment and three cycles of adjuvant TMZ treatment, the
performances of 7 patients remained stable in all six cog-
nitive domains, the performances of 3 patients improved in
one domain, the performances of 2 patients deteriorated in
two domains, and the performances of 1 patient improved
in one domain and deteriorated in another.
Discussion
This study is the first to prospectively examine cognitive
functioning of GBM patients at different points in time
during combined radio-chemotherapy treatment. Consis-
tent with findings in the literature, the majority of the
patients already had multiple cognitive deficits preceding
RT treatment [3, 4]. The current findings suggest that,
overall, cognitive functioning remains rather stable dur-
ing treatment and that the addition of TMZ to RT does
not necessarily lead to an additional deterioration in
cognitive functioning during the first 6 months after
diagnosis. For some patients, changes in cognitive func-
tioning did occur. However, those patients had a deteri-
oration in only one or two of the six cognitive domains
assessed, and the number of patients showing cognitive
decline was equal to the number of patients that cogni-
tively improved. Less cognitive changes occur in the
adjuvant TMZ treatment period compared to the RT and
concomitant TMZ treatment period, suggesting that
patients’ cognitive functioning stabilizes in a less intense
treatment period.
An earlier study, using the same neuropsychological test
battery, reported that cognitive decline occurred in high-
grade glioma patients during and following RT [7]. The
present findings suggest that the addition of TMZ to RT,
for GBM patients as a group, does not negatively affect
cognitive functioning and might in fact even have a posi-
tive effect on cognitive performance, compared to the
earlier mentioned cognitive decline of the patients that only
received RT. These findings are also compatible with
another recent study reporting that it is not the treatment,
but the tumor itself and tumor recurrence, that are the
largest determinants of cognitive decline [6].
To conclude, these initial results hold promise for the
future use of combined treatment regimens as far as cog-
nitive functioning is concerned. This study will continue
with further patients, in order to draw more definite and
detailed conclusions. Follow-up data on cognitive func-
tioning will be collected after all six cycles of TMZ and
4 months after the sixth adjuvant TMZ cycle, to be able to
determine possible late effects.
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For now, the finding that cognitive functioning does not
deteriorate during RT and TMZ combined treatment is of
importance for clinical practice. For those professional
caregivers involved in the treatment of GBM patients, it is
important to recognize that combined modality treatment
not only seems to be safe in terms of health-related quality
of life, but also in terms of cognitive functioning.
Acknowledgments We thank Lies Braam for her participation in
tracing patients and Wilmy Cleijne for her invaluable help in testing
patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy
plus concomitant and adjuvant temozolomide for glioblastoma. N
Engl J Med 352:987–996
Table 3 z-scores and delta-scores
Case Information processing speed Psychomotor function Attention
B (z) DB-FU1 DFU1-2 DB-FU2 B (z) DB-FU1 DFU1-2 DB-FU2 B (z) DB-FU1 DFU1-2 DB-FU2
1 21.57 -0.04 0.05 0.01 -0.80 0.37 0.26 0.63 -0.26 0.01 -0.32 -0.31
2 -2.01 0.49 -0.39 0.10 -0.68 -1.51 0.73 -0.78 -2.71 1.19 0.10 1.29
3 -3.82 -2.92
4 0.45 0.41 -0.71 -0.30 -1.06 1.28 -1.33 -0.05 0.67 0.45 -0.24 0.21
5 -3.33 0.44 -0.39 0.05 0.49 -0.52 0.33 -0.19 -1.92 0.45 -0.43 0.02
6 -3.69 0.60 0.39 0.99 -1.93 1.22 -1.33 -0.11 -4.44 -0.10 -0.33 -0.43
7 -3.10 -0.01 -0.82 -0.83 -1.00 -1.80 -1.70 -3.50 -0.86 -0.86 -1.64 -2.50
8 -0.73 0.34 -0.23 0.11 0.84 -0.17 0.02 -0.15 -0.39 -0.05 0.52 0.47
9 -0.13 -0.50 -0.23 -0.73 -1.35 0.26 -0.47 -0.21 0.07 -0.27 -0.48 -0.75
10 -2.18 -0.37 -0.80 -1.17 -0.23 1.51 0.47 1.98 -1.88 -0.21 -0.60 -0.81
11 -1.01 -1.13 0.40 -0.73 -0.09 -1.04 0.33 -0.71 -1.52 -2.16 -0.40 -2.56
12 -2.21 0.71 -0.34 0.37 0.99 -0.73 -0.41 -1.14 -1.21 1.47 -0.37 1.10
13 -1.50 0.07 0.05 0.12 -3.00 1.78 -0.13 1.65 -1.34 0.50 -0.34 0.16
Case Verbal memory Working memory Executive functioning
B (z) DB-FU1 DFU1-2 DB-FU2 B (z) DB-FU1 DFU1-2 DB-FU2 B (z) DB-FU1 DFU1-2 DB-FU2
1 0.40 0.44 -0.27 0.17 -1.39 0.15 0.36 0.51 -2.45 0.39 -0.76 -0.37
2 -0.05 0.02 -0.17 -0.15 -1.11 -0.22 0.49 0.27 -1.42 1.01 -0.41
3 -0.76 -0.65 0.52 -0.13 -1.32 0.16 -0.70 -0.54 -5.24
4 -0.80 0.19 0.83 1.02 0.53 0.43 -0.49 -0.06 -1.31 2.24 -0.54 1.70
5 -0.85 0.66 0.38 1.04 -1.75 0.32 -1.11 -0.79 -2.72 1.52 -0.79 0.73
6 -0.57 -0.02 -0.21 -0.23 -2.63 1.40 -0.73 0.67 -4.40 1.36 0.78 2.14
7 -1.49 0.09 0.41 0.50 -2.88 -1.03 -0.38 -1.41 -2.24 -0.37 -0.40 -0.77
8 0.07 0.24 0.43 0.67 -0.87 -0.17 -0.05 -0.22 -0.23 -0.58 0.97 0.39
9 0.35 -0.25 0.19 -0.06 0.10 -0.20 -0.07 -0.27 -2.00 0.61 0.07 0.68
10 -3.28 0.20 0.91 1.11 1.02 -0.43 -0.26 -0.69 -3.43 -2.30 0.39 -1.91
11 0.35 -0.19 -0.11 -0.30 -0.19 -0.77 0.57 -0.20 -1.13 -0.33 -1.41 -1.74
12 -0.99 0.16 -0.10 0.06 -1.96 1.65 -1.63 0.02 -2.08 1.25 -0.80 0.45
13 0.05 0.41 0.05 0.46 -0.91 0.27 0.42 0.69 -1.25 0.19 -0.66 -0.47
Individual z-scores and delta (D)-scores per patient for all six cognitive domains. Performance is relative to that of age, gender, and education-
matched healthy controls. A higher baseline z-score means better performance. A negative delta score indicates deterioration, a positive delta
score indicates amelioration. Significant deviations [individual z-scores of 1.5 or more below that of healthy controls (z B -1.5)] and changes
[individual changes of 1.5 z-score or more (z D C 1.5 or z D B -1.5)] are depicted in bold.
B Baseline (after surgery, but before RT and concomitant TMZ), FU1 follow-up 1 (after 6 weeks of conventional RT and concomitant TMZ, but
before adjuvant TMZ), FU2 follow-up 2 (after three cycles of adjuvant TMZ)
J Neurooncol (2010) 97:89–94 93
123
2. Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients
with brain tumours. Lancet Neurol 3:159–168
3. Tucha O, Smely C, Preier M, Lange KW (2000) Cognitive deficits
before treatment among patients with brain tumors. Neurosurgery
47:324–333
4. Klein M, Taphoorn MJ, Heimans JJ et al (2001) Neurobehavioral
status and health-related quality of life in newly diagnosed high-
grade glioma patients. J Clin Oncol 19:4037–4047
5. Schmidinger M, Linzmayer L, Becherer et al (2003) Psycho-
metric- and quality-of-life assessment in long-term glioblastoma
survivors. J Neurooncol 63:55–61
6. Brown PD, Jensen AW, Felten SJ et al (2006) Detrimental effects
of tumor progression on cognitive function of patients with high-
grade glioma. J Clin Oncol 24:5427–5433
7. Bosma I, Vos MJ, Heimans JJ et al (2007) The course of neurocog-
nitive functioning in high-grade glioma patients. Neuro-oncology
9:53–62
8. Correa DD, Maron L, Harder H et al (2007) Cognitive functions
in primary central nervous system lymphoma: literature review
and assessment guidelines. Ann Oncol 18(7):1145–1151
9. Taphoorn MJ, Stupp R, Coens C et al (2005) Health-related
quality of life in patients with glioblastoma: a randomised con-
trolled trial. Lancet Oncol 6:937–944
10. Lezak MD (1995) Neuropsychological assessment. Oxford Uni-
versity Press, New York
11. Houx PJ, Jolles J (1994) Vulnerability factors for age-related
cognitive decline. In: Isaacson RL, Jensen KF (eds) The vulner-
able brain and environmental risks. Plenum, New York, pp 25–41
12. Sternberg S (1975) Memory scanning: new findings and current
controversies. Q J Exp Psychol 27:1–32
94 J Neurooncol (2010) 97:89–94
123
